All In MedTech

Device type · OZO

Automated Insulin Dosing , Threshold Suspend

FDA groups similar devices under a three-letter product code. This page gathers what FDA's public data says about OZO: how it is classified, what has been cleared or approved, and what has been reported and recalled.

Last checked: Nov 19, 2026Source: openFDAMethods & limitations

Product code

OZO

Clinical Chemistry

Device class

Class III

FDA decisions since 2015

4

510(k), De Novo and PMA

Adverse event reports

1,554

Received Nov 1, 2025 to Nov 19, 2026

How FDA classifies it

Device type
Automated Insulin Dosing , Threshold Suspend
Product code
OZO
Device class
Class III
Review panel
Clinical Chemistry

Latest FDA decisions

All decisions for OZO

1 more FDA decisions with a free account

Reports received

1,554

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

1,371

88% of reports

Injury reports

174

11% of reports

Death reports

9

0.6% of reports

Adverse event reports received per month

By the date FDA received each report, stacked by event type. The newest month is incomplete.

Open in the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 231,69139070
Jan 241,34461680
Feb 241,13214951
Mar 241,12617380
Apr 249088720
May 241,0899680
Jun 2497111490
Jul 2482155780
Aug 24531145110
Sep 244344600
Oct 243684440
Nov 2432214500
Dec 244953430
Jan 254426400
Feb 252671720
Mar 253133530
Apr 2539513130
May 253522820
Jun 252362460
Jul 252431820
Aug 251992520
Sep 253221310
Oct 251792000
Nov 25118500
Dec 251701420
Jan 261551200
Feb 26179920
Mar 261321100
Apr 26122910
May 26791700
Jun 261043600
Jul 26841400
Aug 26752110
Sep 26741430
Oct 26791200
Nov 260000

Manufacturers named most often

Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.

Device problems as coded

Last 12 months. FDA's terms. A report can carry several.

  • Break446
  • Obstruction of Flow375
  • Battery Problem339

7 more in this ranking with a free account

Patient problems as coded

Last 12 months. FDA's terms. A report can carry several.

  • No Clinical Signs, Symptoms or Conditions1,257
  • Hyperglycemia211
  • Hypoglycemia72

7 more in this ranking with a free account

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Medtronic MiniMed, Inc.

    Z-1740-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026

    Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...

    Cause as FDA categorized it: Device Design

  • Medtronic MiniMed, Inc.

    Z-1751-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026

    Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...

    Cause as FDA categorized it: Device Design

  • Medtronic MiniMed, Inc.

    Z-1259-2025 · Started Jan 31, 2025 · Posted by FDA Mar 3, 2025

    Reason given: All Medtronic MiniMed pumps (Paradigm series, Minimed 530G, 6XX series, and 7XX series) were found to have the potential for abnormal insulin delivery due to changes in air pressure, which can be found during airplane take-off or landing. An unexpected additional dose of insulin, which can occur during take-off, can...

    Cause as FDA categorized it: Device Design

8 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.